Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Merck & Co.’s second-quarter earnings dropped 52 percnet on acquisition and other charges as sales of its key drugs weren’t as strong as in recent quarters.
The drug giant also narrowed its 2010 earnings forecast while trimming the top end of its sales view for the year. Get the full story »
By Bruce Japsen | The looming decline in sales from the blockbuster diabetes drug Actos
figured into Takeda Pharmaceutical Co.’s decision Wednesday to slash
nearly 1,600 U.S. jobs — including hundreds in Chicago’s northern
suburbs.
Japan’s largest drug maker operates from its U.S. base in Deerfield
under the name Takeda Pharmaceuticals North America Inc. It faces
competition in the next two years from upcoming generic versions of its
flagship product, the diabetes prescription Actos.
Dow Jones Newswires | Crystal Lake-based AptarGroup Inc.’s first-quarter earnings climbed by nearly half on strength in its core beauty-and-home segment, as the product-dispenser maker projected stronger earnings in the current quarter than analysts expected.
It sees earnings of 60 cents to 65 cents a share, above the average estimate of 56 cents a share from a survey of analysts by Thomson Reuters.
